Agriculture · Founded 2000 · www.nathbiogenes.com · BSE 537291 · NSE NATH BIOGEN · ISIN INE448G01010
No Notes Added Yet
Business
Nath Bio-Genes (India) Ltd. is an agricultural biotechnology company primarily engaged in the research, development, production, processing, and marketing of hybrid seeds. The company's core business model revolves around developing high-yielding and disease-resistant seed varieties for various crops, selling these seeds to farmers through an extensive distribution network across different states in India. It generates revenue by providing solutions to enhance agricultural productivity and farmer income.
Revenue Mix
The company's revenue is primarily derived from the sale of hybrid seeds. While precise percentage breakdowns can vary and are not always detailed publicly, Nath Bio-Genes typically focuses on a portfolio of key crops including:
Field Crops: Cotton (e.g., Bt cotton hybrids), Maize, Paddy (Rice), Pearl Millet, Sorghum, Sunflower.
Vegetable Crops: Okra, Tomato, Chilli, Brinjal, Cabbage, Cauliflower, Gourds, etc.
The primary revenue drivers are usually cotton and maize seeds, followed by paddy and various vegetable seeds.
Industry
The Indian agriculture industry, particularly the seed sector, is vast, diverse, and highly dependent on climatic conditions and government policies. It is characterized by the coexistence of large multi-national companies, established domestic players, and numerous smaller regional companies. Nath Bio-Genes is positioned as an established Indian seed company with a significant presence in hybrid seeds, particularly in certain regions and specific crops like cotton and maize. It competes with global giants like Bayer (erstwhile Monsanto) and Syngenta, as well as strong domestic players such as Kaveri Seed Company, Nuziveedu Seeds, and JK Agri Genetics. Its positioning relies on its R&D capabilities, regional market penetration, and product portfolio catering to local agricultural needs.
MOAT
Nath Bio-Genes possesses certain competitive advantages, though not necessarily a wide economic moat in a highly competitive industry:
R&D Capabilities: Long-standing focus on developing proprietary hybrid seed varieties through its in-house R&D, leading to specific crop traits like yield improvement and disease resistance.
Distribution Network: An established and wide distribution network across key agricultural states in India, ensuring product reach to farmers.
Farmer Trust: Over decades of operation, the company has built a level of brand recognition and trust among farmers in its target markets due to consistent product performance.
Product Portfolio: A diverse portfolio across field and vegetable crops, reducing over-reliance on a single crop.
Growth Drivers
Increased Adoption of Hybrid Seeds: Continued shift from traditional/local varieties to higher-yielding hybrid seeds by Indian farmers seeking better productivity and income.
Population Growth & Food Security: Rising population and the need for enhanced food production will drive demand for quality seeds.
Product Innovation & Pipeline: Introduction of new, superior hybrid varieties (e.g., drought-tolerant, pest-resistant) through ongoing R&D can drive market share gains.
Market Expansion: Increasing presence in untapped or under-penetrated agricultural regions within India.
Government Focus on Agriculture: Supportive government policies, subsidies, and schemes aimed at boosting agricultural output and farmer welfare can indirectly benefit seed companies.
Risks
Monsoon Dependency: Agricultural output and seed demand are heavily dependent on timely and adequate monsoons. Adverse weather conditions (droughts, floods) can significantly impact sales.
Regulatory Changes: Government policies related to seed pricing (e.g., cap on Bt cotton seed prices), approval processes for new biotech crops, and intellectual property rights can impact profitability and R&D investment.
Intense Competition: The seed market is highly competitive with both large multinational and strong domestic players, leading to pricing pressures and market share battles.
Pest and Disease Outbreaks: Emergence of new pests or diseases can necessitate continuous R&D investment and render existing seed varieties less effective.
Working Capital Management: The seasonal nature of the seed business requires significant working capital management for production, inventory, and receivables.
Genetic Contamination/Quality Issues: Any issues with seed quality or genetic purity can severely damage brand reputation and lead to financial losses.
Management & Ownership
Nath Bio-Genes (India) Ltd. is promoted by the Nath family, with Mr. Satish Nath as the Chairman & Managing Director. The management team comprises experienced professionals in the agriculture and biotechnology sectors. The promoter group typically holds a significant stake in the company, indicating strong alignment of interests. The company is publicly listed, with the remaining shares held by institutional investors, high net worth individuals, and the public.
Outlook
Nath Bio-Genes operates in a fundamental sector critical for India's food security and rural economy. The long-term demand for quality hybrid seeds is expected to remain robust due to population growth and the continuous need for higher agricultural productivity. The company's established R&D capabilities and widespread distribution network position it to capitalize on this trend. However, the business faces significant cyclicality due to weather dependence and regulatory uncertainties, particularly regarding GM crops and seed pricing. Intense competition and the continuous need for R&D investment to stay relevant are ongoing challenges. Success hinges on its ability to consistently develop and market superior seed varieties while effectively managing operational and regulatory risks in a dynamic agricultural landscape.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 43 | 244 | 32 | 37 | 52 | 284 | 44 | 66 | 52 | 328 |
| Other Income | 0 | 0 | 0 | 0 | 4 | 2 | 2 | 2 | 2 | 2 |
| Total Income | 43 | 244 | 32 | 37 | 56 | 285 | 46 | 68 | 54 | 330 |
| Total Expenditure | 39 | 207 | 27 | 29 | 52 | 254 | 38 | 62 | 47 | 293 |
| Operating Profit | 4 | 37 | 5 | 9 | 4 | 31 | 8 | 5 | 7 | 37 |
| Interest | 1 | 2 | 3 | 4 | 1 | 3 | 4 | 5 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 1 | 1 |
| Profit Before Tax | 2 | 34 | 1 | 4 | 2 | 29 | 3 | 2 | 2 | 33 |
| Provision for Tax | 1 | 0 | -0 | 1 | 1 | 1 | 1 | 1 | 3 | 1 |
| Profit After Tax | 2 | 33 | 1 | 3 | 1 | 28 | 3 | 2 | -0 | 32 |
| Adjustments | 1 | 0 | -0 | 0 | 1 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 3 | 33 | 1 | 3 | 1 | 28 | 3 | 2 | -0 | 32 |
| Adjusted Earnings Per Share | 1.4 | 17.6 | 0.6 | 1.4 | 0.8 | 14.9 | 1.4 | 0.8 | -0 | 17 |
| #(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Net Sales | 124 | 138 | 278 | 301 | 333 | 365 | 445 | 490 |
| Other Income | 1 | 1 | 2 | 1 | 1 | 5 | 8 | 8 |
| Total Income | 125 | 138 | 280 | 302 | 333 | 369 | 453 | 498 |
| Total Expenditure | 109 | 118 | 241 | 252 | 283 | 315 | 392 | 440 |
| Operating Profit | 16 | 20 | 39 | 50 | 51 | 55 | 60 | 57 |
| Interest | 2 | 4 | 11 | 10 | 9 | 11 | 16 | 18 |
| Depreciation | 5 | 5 | 3 | 3 | 3 | 4 | 4 | 4 |
| Exceptional Income / Expenses | 0 | 0 | -89 | 0 | 3 | 1 | 6 | 5 |
| Profit Before Tax | 9 | 12 | -63 | 36 | 42 | 41 | 46 | 40 |
| Provision for Tax | -0 | 1 | 4 | 1 | 2 | 2 | 5 | 6 |
| Profit After Tax | 9 | 12 | -67 | 35 | 40 | 39 | 42 | 37 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 9 | 12 | -67 | 35 | 40 | 39 | 42 | 37 |
| Adjusted Earnings Per Share | 0 | 0 | -35.5 | 18.4 | 20.8 | 20.3 | 21.9 | 19.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 22% | 14% | 26% | 0% |
| Operating Profit CAGR | 9% | 6% | 25% | 0% |
| PAT CAGR | 8% | 6% | 28% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -18% | -13% | -16% | 2% |
| ROE Average | 6% | 6% | 1% | 7% |
| ROCE Average | 8% | 7% | 3% | 8% |
| #(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 46 | 57 | 542 | 573 | 610 | 644 | 680 |
| Minority's Interest | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Borrowings | 1 | 1 | 1 | 0 | 5 | 13 | 17 |
| Other Non-Current Liabilities | 1 | 1 | 3 | 3 | 3 | 4 | 5 |
| Total Current Liabilities | 72 | 98 | 194 | 216 | 262 | 365 | 395 |
| Total Liabilities | 119 | 157 | 739 | 793 | 880 | 1026 | 1097 |
| Fixed Assets | 21 | 38 | 245 | 244 | 249 | 250 | 249 |
| Other Non-Current Assets | 2 | 0 | 27 | 29 | 59 | 86 | 69 |
| Total Current Assets | 96 | 120 | 468 | 520 | 572 | 690 | 779 |
| Total Assets | 119 | 157 | 739 | 793 | 880 | 1026 | 1097 |
| #(Fig in Cr.) | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 3 | 29 | 4 | 38 | 77 | 89 |
| Cash Flow from Operating Activities | 0 | 14 | 17 | 38 | 75 | 18 | -13 |
| Cash Flow from Investing Activities | 0 | -21 | -20 | -3 | -27 | -4 | 3 |
| Cash Flow from Financing Activities | 0 | 6 | -22 | -2 | -8 | -2 | -4 |
| Net Cash Inflow / Outflow | 0 | -1 | -25 | 34 | 39 | 11 | -13 |
| Closing Cash & Cash Equivalent | 0 | 2 | 4 | 38 | 77 | 89 | 76 |
| # | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0 | -35.46 | 18.43 | 20.85 | 20.31 | 21.91 |
| CEPS(Rs) | 8.69 | 10.16 | -33.84 | 20.01 | 22.56 | 22.32 | 23.99 |
| DPS(Rs) | 0 | 0 | 2 | 2 | 2 | 2 | 2 |
| Book NAV/Share(Rs) | 0 | 0 | 285.16 | 301.61 | 320.94 | 339.08 | 358.06 |
| Core EBITDA Margin(%) | 11.84 | 14.45 | 13.37 | 16.25 | 15.02 | 13.72 | 11.82 |
| EBIT Margin(%) | 8.78 | 11.6 | -18.96 | 15.44 | 15.26 | 14.06 | 14.03 |
| Pre Tax Margin(%) | 7.32 | 8.93 | -22.79 | 12 | 12.5 | 11.12 | 10.4 |
| PAT Margin (%) | 7.42 | 8.53 | -24.21 | 11.62 | 11.91 | 10.58 | 9.35 |
| Cash Profit Margin (%) | 11.22 | 11.8 | -23.1 | 12.62 | 12.89 | 11.62 | 10.24 |
| ROA(%) | 7.73 | 8.5 | -15.03 | 4.57 | 4.74 | 4.05 | 3.92 |
| ROE(%) | 20.12 | 22.76 | -22.48 | 6.28 | 6.7 | 6.15 | 6.28 |
| ROCE(%) | 19.09 | 23.88 | -14.84 | 7.09 | 7.26 | 6.9 | 7.88 |
| Receivable days | 36.68 | 44.32 | 69.85 | 110.74 | 105.14 | 91.63 | 71.47 |
| Inventory Days | 193.69 | 189.43 | 195.06 | 259.3 | 240.4 | 284.23 | 323.33 |
| Payable days | 1576.65 | -4219.16 | 1503.38 | 744.29 | -1457.17 | -249 | -367.18 |
| PER(x) | 0 | 0 | 0 | 7.69 | 8.33 | 7.18 | 5.83 |
| Price/Book(x) | 0 | 0 | 0.75 | 0.47 | 0.54 | 0.43 | 0.36 |
| Dividend Yield(%) | 0 | 0 | 0.94 | 1.41 | 1.15 | 1.37 | 1.57 |
| EV/Net Sales(x) | 0.19 | 0.24 | 1.78 | 1.12 | 1.09 | 0.85 | 0.69 |
| EV/Core EBITDA(x) | 1.54 | 1.6 | 12.65 | 6.79 | 7.18 | 5.69 | 5.05 |
| Net Sales Growth(%) | 0 | 11.13 | 102.15 | 8.26 | 10.37 | 9.71 | 21.98 |
| EBIT Growth(%) | 0 | 46.76 | -430.58 | 188.13 | 9.13 | 1.09 | 21.71 |
| PAT Growth(%) | 0 | 27.66 | -673.7 | 151.96 | 13.16 | -2.57 | 7.85 |
| EPS Growth(%) | 0 | 0 | -583.1 | 151.98 | 13.11 | -2.57 | 7.85 |
| Debt/Equity(x) | 0.25 | 0.33 | 0.17 | 0.18 | 0.18 | 0.19 | 0.2 |
| Current Ratio(x) | 1.34 | 1.22 | 2.41 | 2.4 | 2.18 | 1.89 | 1.97 |
| Quick Ratio(x) | 0.42 | 0.43 | 1.27 | 1.44 | 1.3 | 0.96 | 0.83 |
| Interest Cover(x) | 6.02 | 4.35 | -4.96 | 4.49 | 5.52 | 4.78 | 3.86 |
| Total Debt/Mcap(x) | 0 | 0 | 0.23 | 0.39 | 0.33 | 0.44 | 0.57 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 |
| FII | 0.27 | 0.21 | 0.18 | 0.19 | 0.21 | 0.41 | 0.32 | 0.31 | 0.22 | 0.26 |
| DII | 4.37 | 4.37 | 4.37 | 4.37 | 3.95 | 2.25 | 0.76 | 0.01 | 0.01 | 0.01 |
| Public | 49.76 | 49.82 | 49.85 | 49.84 | 50.25 | 51.74 | 53.32 | 54.08 | 54.17 | 54.13 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| DII | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.04 | 0.01 | 0 | 0 | 0 |
| Public | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.98 | 1.01 | 1.03 | 1.03 | 1.03 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +22% | +14% | +26% | — |
| Operating Profit CAGR | +9% | +6% | +25% | — |
| PAT CAGR | +8% | +6% | +28% | — |
| Share Price CAGR | -18% | -13% | -16% | +2% |
| ROE Average | +6% | +6% | +1% | +7% |
| ROCE Average | +8% | +7% | +3% | +8% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 | 45.6 |
| FII | 0.27 | 0.21 | 0.18 | 0.19 | 0.21 | 0.41 | 0.32 | 0.31 | 0.22 | 0.26 |
| DII | 4.37 | 4.37 | 4.37 | 4.37 | 3.95 | 2.25 | 0.76 | 0.01 | 0.01 | 0.01 |
| Public | 49.76 | 49.82 | 49.85 | 49.84 | 50.25 | 51.74 | 53.32 | 54.08 | 54.17 | 54.13 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 |
| FII | 0.01 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.01 | 0 | 0 |
| DII | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.04 | 0.01 | 0 | 0 | 0 |
| Public | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.98 | 1.01 | 1.03 | 1.03 | 1.03 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.